Application 205959
- Type
- ANDA
- Sponsor
- PAR PHARM
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 002 | SAXAGLIPTIN | SAXAGLIPTIN | TABLET;ORAL | 5MG | No | No |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| SAXAGLIPTIN | SAXAGLIPTIN | Glenmark Pharmaceuticals Inc., USA | e286ffd4-c598-47fb-af06-2e15f7e6f99f | 2026-01-27 | Warnings, Adverse reactions | SAXAGLIPTIN SAXAGLIPTIN |
| Saxagliptin | SAXAGLIPTIN | Mylan Pharmaceuticals Inc. | 6e8d8c4f-96eb-4b64-9c8c-4a5448a23a78 | 2025-02-28 | Warnings, Adverse reactions | Saxagliptin SAXAGLIPTIN |
| Saxagliptin | SAXAGLIPTIN | Aurobindo Pharma Limited | f3ea58bb-0002-4a5d-9213-7e9066e3dc9c | 2024-12-04 | Warnings, Adverse reactions | Saxagliptin SAXAGLIPTIN |
Documents#
| Document | Submission type | Date |
|---|---|---|
| 45085 | ORIG | 2016-08-22 |